Schizophrenia Research Forum: Animal Models

Name	DA-related behavior	Gating	Cognitive behavior	Social behavior	Molecular morphological signature	Response to APD
Basolateral Amygdala Picrotoxin Infusion-Rat						GABA antagonism in BLA decreases GAD67 in HPC, GABA antagonism in BLA increases HPC LTP
Ceftriaxone-Induced Glutamate Transporter Upregulation		Impairs PPI.
Methamphetamine Treatment-Chronic		Disrupted PPI	Impaired recognition memory		Increased TUNEL-positive cells in mPFC	Memory impairment blocked by GABA(B) agonist, PPI disruption and TUNEL-positive cell counts blocked by olanzapine and risperidone
Neonatal EGF Treatment	Increased locomotor activity	Impaired PPI		Reduced social behavior	Enhanced cAMP response to D2R activation	Haloperidol reduced motoric activity, clozapine improved social deficit
CHX Induced Glutathione Depletion			Disrupted short-term spatial memory		Reduced striatal and cortex glutathione levels
Disinhibition of Ventral Hippocampus	Increased locomotor activity	Disrupted PPI	Disrupted fear conditioning		Increased accumbens and cortex dopamine	Haloperidol and clozapine block hyperactivity but no effect on PPI deficit
NMDA Receptor Antagonist Rx (MK801, PCP, Ketamine)-Acute	Increases locomotor activity and stereotopy, ataxia	Disrupted PPI 1 day after PCP, and 15 minutes after PCP, but not 7 or 28 days later, abnormal latent inhibition	Decreased working memory, disrupted fear conditioning, long-term spatial memory deficits, impaired passive-avoidance, recognition memory deficit	Impaired social interaction	Impaired LTP, decreased AMPA receptor density	Enhanced locomotor responses blocked by APD, glycine transporter-1 inhibition rescues LTP, PPI disruption attenuated by admatine, glycine, D-serine, not D-cycloserine, fear conditioning disruption prevented by clozapine, but not haloperidol, LI abnormalities reversed by risperidone and M100907, passive avoidance impairment reversed by lurasidone, recognition memory deficit reversed by clozapine and D-serine, but not haloperidol